| Market Cap | 131.62Cr 117.89Cr 108.76Cr 98Cr 184.05Cr 13TCr 187.02Cr 1.3TCr 517.67Cr 6.56TCr 493.96Cr 483.44Cr 21TCr | P/E 2026 * |
-4.77x | P/E 2027 * | -3.67x |
|---|---|---|---|---|---|
| Enterprise Value | 71Cr 63Cr 58Cr 53Cr 99Cr 6.74TCr 100.58Cr 697.86Cr 278.4Cr 3.53TCr 265.66Cr 260Cr 11TCr | EV / Sales 2026 * |
16.9x | EV / Sales 2027 * | 16.9x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 131.62Cr | |
| +0.34% | -3.03% | +37.45% | +61.06% | 6.41TCr | |
| +0.98% | +2.26% | +12.91% | +82.98% | 5.55TCr | |
| +1.75% | +2.76% | +12.38% | +103.69% | 5.3TCr | |
| -1.43% | -0.57% | +26.10% | +52.86% | 4.6TCr | |
| -0.48% | -3.86% | +17.27% | +117.99% | 4.25TCr | |
| +0.82% | -2.06% | +227.09% | +922.41% | 4.04TCr | |
| -0.26% | -4.20% | +10.86% | +45.18% | 3.23TCr | |
| -2.07% | +44.58% | +102.84% | +88.74% | 3.45TCr | |
| -2.72% | -8.79% | +22.58% | -5.63% | 2.42TCr | |
| Average | -0.41% | +3.82% | +52.16% | +163.25% | 4.36TCr | |
| Weighted average by Cap. | -0.11% | +3.13% | +49.26% | +160.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.18Cr 3.75Cr 3.46Cr 3.13Cr 5.85Cr 398.26Cr 5.94Cr 41Cr 16Cr 208.43Cr 16Cr 15Cr 660.15Cr | 5.34Cr 4.78Cr 4.41Cr 3.99Cr 7.47Cr 508.68Cr 7.59Cr 53Cr 21Cr 266.22Cr 20Cr 20Cr 843.18Cr |
| Net income | -25Cr -22Cr -20Cr -18Cr -34Cr -2.35TCr -35Cr -242.92Cr -97Cr -1.23TCr -92Cr -91Cr -3.89TCr | -36Cr -32Cr -30Cr -27Cr -51Cr -3.45TCr -52Cr -357.49Cr -142.62Cr -1.81TCr -136.09Cr -133.19Cr -5.72TCr |
| Net Debt | -61Cr -54Cr -50Cr -45Cr -85Cr -5.79TCr -86Cr -599.74Cr -239.26Cr -3.03TCr -228.31Cr -223.44Cr -9.6TCr | -42Cr -37Cr -34Cr -31Cr -58Cr -3.95TCr -59Cr -409.38Cr -163.32Cr -2.07TCr -155.84Cr -152.52Cr -6.55TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
